The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
cyprodinil binds to and results in increased activity of AHR protein cyprodinil results in increased activity of AHR protein cyprodinil results in decreased expression of AHR protein AHR protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein] cyprodinil affects the localization of AHR protein
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein] [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein
cyprodinil binds to APP protein modified form [APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to cyprodinil; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil]
cyprodinil binds to AR protein cyprodinil results in increased activity of AR protein cyprodinil inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; cyprodinil inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] cyprodinil results in increased expression of AR mRNA
cyprodinil results in increased expression of CASP3 mRNA [pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of CASP3 mRNA
cyprodinil results in increased expression of CCNE1 protein fulvestrant inhibits the reaction [cyprodinil results in increased expression of CCNE1 protein]
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein
cyprodinil results in increased expression of CTSD protein fulvestrant inhibits the reaction [cyprodinil results in increased expression of CTSD protein]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein] cyprodinil results in increased expression of CYP1A1 mRNA; cyprodinil results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein]; ARNT protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein]
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein] [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
cyprodinil affects the expression of GPX1 mRNA [pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of GPX1 mRNA
cyprodinil results in increased phosphorylation of H2AX protein [fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein cyprodinil results in increased activity of NR1I2 protein
[cyprodinil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein
ABCG2 protein results in increased transport of ethirimol 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased transport of ethirimol]
fenarimol binds to AR protein Dihydrotestosterone inhibits the reaction [fenarimol results in increased activity of AR protein]; fenarimol inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; fenarimol inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; fenarimol inhibits the reaction [Metribolone results in increased activity of AR protein]
fenarimol results in decreased activity of CYP19A1 protein fenarimol results in increased expression of CYP19A1 mRNA; fenarimol results in increased expression of CYP19A1 protein
[fenarimol co-treated with acephate] affects the expression of CYP1A1 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP1A1 protein; [fenarimol co-treated with vinclozolin] affects the expression of CYP1A1 protein
[fenarimol co-treated with acephate] affects the expression of CYP1A2 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP1A2 protein; [fenarimol co-treated with vinclozolin] affects the expression of CYP1A2 protein
[fenarimol co-treated with acephate] affects the expression of CYP2B2 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP2B2 protein; [fenarimol co-treated with vinclozolin] affects the expression of CYP2B2 protein
[fenarimol co-treated with acephate] affects the expression of CYP2E1 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP2E1 protein; [fenarimol co-treated with vinclozolin] affects the expression of CYP2E1 protein
fenarimol binds to ESR1 protein fenarimol results in increased activity of ESR1 protein [Chlorpyrifos co-treated with fenarimol co-treated with Estradiol] results in increased activity of ESR1 protein; afimoxifene inhibits the reaction [[fenarimol co-treated with Estradiol] results in increased activity of ESR1 protein]; afimoxifene inhibits the reaction [fenarimol results in increased activity of ESR1 protein]; fenarimol binds to and results in increased activity of ESR1 protein; fenarimol promotes the reaction [Estradiol results in increased activity of ESR1 protein]; Fulvestrant inhibits the reaction [[fenarimol co-treated with Estradiol] results in increased activity of ESR1 protein]; Fulvestrant inhibits the reaction [fenarimol results in increased activity of ESR1 protein] fenarimol results in decreased expression of ESR1 mRNA
fenarimol binds to and results in increased activity of ESR2 protein; fenarimol promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] fenarimol results in increased activity of ESR2 protein fenarimol results in increased expression of ESR2 mRNA
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]
[APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to mepanipyrim; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein] [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein] [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein
pyrimethanil binds to APP protein modified form [APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to pyrimethanil; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil]
pyrimethanil results in increased expression of AR mRNA pyrimethanil inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]
[pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of CASP3 mRNA pyrimethanil affects the expression of CASP3 mRNA
[N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased expression of CYP3A4 mRNA
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein] [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
pyrimethanil affects the expression of GPX1 mRNA [pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of GPX1 mRNA
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]
[N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased activity of NR1I2 protein
[pyrimethanil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2
browse the term
